Published in J Toxicol Environ Health A on January 09, 2004
Arsenic exposure and toxicology: a historical perspective. Toxicol Sci (2011) 2.63
Immunotoxicity and biodistribution analysis of arsenic trioxide in C57Bl/6 mice following a 2-week inhalation exposure. Toxicol Appl Pharmacol (2009) 0.94
Mathematical model insights into arsenic detoxification. Theor Biol Med Model (2011) 0.89
Relative pesticide and exposure route contribution to aggregate and cumulative dose in young farmworker children. Int J Environ Res Public Health (2012) 0.85
Relative bioavailability and bioaccessibility and speciation of arsenic in contaminated soils. Environ Health Perspect (2011) 0.83
Mathematical modeling of the effects of glutathione on arsenic methylation. Theor Biol Med Model (2014) 0.81
Mechanism of selenium-induced inhibition of arsenic-enhanced UVR carcinogenesis in mice. Environ Health Perspect (2008) 0.78
A HIERARCHICAL FUNCTIONAL DATA ANALYTIC APPROACH FOR ANALYZING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS. Environmetrics (2013) 0.75
Interaction effects of lead on bioavailability and pharmacokinetics of arsenic in the rat. Environ Geochem Health (2013) 0.75
Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci (2011) 2.03
Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal (2007) 1.61
Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. Toxicol Sci (2008) 1.51
Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol Sci (2005) 1.35
Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. Toxicology (2006) 1.34
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci (2010) 1.30
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology (2010) 1.28
Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Crit Rev Toxicol (2010) 1.23
Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol (2006) 1.19
Correlation of expression of the actin filament-bundling protein espin with stereociliary bundle formation in the developing inner ear. J Comp Neurol (2004) 1.15
Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics? Environ Health Perspect (2013) 1.14
Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study. Toxicol Sci (2003) 1.12
Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci (2013) 1.10
Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci (2004) 1.07
Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. Environ Sci Technol (2005) 1.04
Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci (2013) 1.03
Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A (2006) 1.03
Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci (2010) 1.03
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A (2013) 1.00
Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg (2005) 1.00
A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci (2007) 1.00
Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. Toxicol Sci (2010) 0.99
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol Sci (2013) 0.98
Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology (2006) 0.98
Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol (2006) 0.98
Thermal burn and electrical injuries among electric utility workers, 1995-2004. Burns (2006) 0.97
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol (2008) 0.96
The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul Toxicol Pharmacol (2006) 0.96
Can case study approaches speed implementation of the NRC report: "toxicity testing in the 21st century: a vision and a strategy?". ALTEX (2011) 0.95
Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett (2007) 0.95
Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound. Toxicol Sci (2010) 0.93
Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. Regul Toxicol Pharmacol (2007) 0.93
Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol (2012) 0.93
The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX (2012) 0.93
Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci (2011) 0.92
Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. Mutat Res (2012) 0.92
Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein. Inhal Toxicol (2008) 0.91
Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol (2008) 0.91
Making sense of human biomonitoring data: findings and recommendations of a workshop. J Expo Sci Environ Epidemiol (2007) 0.91
Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol In Vitro (2009) 0.91
Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol (2008) 0.91
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol (2003) 0.90
Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol (2007) 0.89
A PBPK model for evaluating the impact of aldehyde dehydrogenase polymorphisms on comparative rat and human nasal tissue acetaldehyde dosimetry. Inhal Toxicol (2008) 0.89
Hershey Medical Center Technical Workshop Report: optimizing the design and interpretation of epidemiologic studies for assessing neurodevelopmental effects from in utero chemical exposure. Neurotoxicology (2006) 0.88
Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect (2015) 0.88
Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ Mol Mutagen (2010) 0.88
Pharmacokinetic modeling of manganese in the rat IV: Assessing factors that contribute to brain accumulation during inhalation exposure. J Toxicol Environ Health A (2008) 0.87
Hormesis and adaptive cellular control systems. Dose Response (2008) 0.86
Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci (2010) 0.86
Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol Sci (2009) 0.85
Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. Toxicol Sci (2011) 0.85
Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J Toxicol Environ Health A (2007) 0.85
Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. Inhal Toxicol (2008) 0.84
Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol (2011) 0.84
Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment. J Toxicol Environ Health A (2010) 0.84
Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol (2006) 0.84
Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse. Environ Health Perspect (2014) 0.84
Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul Toxicol Pharmacol (2006) 0.83
In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. Toxicol In Vitro (2011) 0.83
Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. J Toxicol Environ Health A (2008) 0.83
Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol (2002) 0.83
Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. Environ Health Perspect (2014) 0.82
Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul Toxicol Pharmacol (2011) 0.82
Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal Toxicol (2003) 0.82
Evaluation of gene expression changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites. Environ Mol Mutagen (2012) 0.81
Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. J Toxicol Environ Health A (2007) 0.81
Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). Regul Toxicol Pharmacol (2008) 0.81
Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol (2011) 0.81
Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal (2007) 0.81
A physiologically based pharmacokinetic model for the oxime TMB-4: simulation of rodent and human data. Arch Toxicol (2013) 0.81
In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. Toxicol In Vitro (2013) 0.81
An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol Sci (2002) 0.81
Lactational transfer of manganese in rats: predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. Toxicol Sci (2009) 0.80
How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review. Toxicol Appl Pharmacol (2008) 0.80
Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal (2007) 0.80
Formaldehyde exposure and leukemia: critical review and reevaluation of the results from a study that is the focus for evidence of biological plausibility. Crit Rev Toxicol (2013) 0.80
Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. J Toxicol Environ Health A (2007) 0.80
Kinetics of arsenic methylation by freshly isolated B6C3F1 mouse hepatocytes. Chem Biol Interact (2006) 0.80
A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A (2007) 0.80
Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment. J Toxicol (2012) 0.80
Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report. Toxicol Appl Pharmacol (2007) 0.80
Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. J Toxicol Environ Health A (2007) 0.79
Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhal Toxicol (2002) 0.79